DOP2012000006A - Agonista de gpr119 - Google Patents
Agonista de gpr119Info
- Publication number
- DOP2012000006A DOP2012000006A DO2012000006A DO2012000006A DOP2012000006A DO P2012000006 A DOP2012000006 A DO P2012000006A DO 2012000006 A DO2012000006 A DO 2012000006A DO 2012000006 A DO2012000006 A DO 2012000006A DO P2012000006 A DOP2012000006 A DO P2012000006A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- gpr119 agonist
- gpr119
- agonist
- obesity
- diabetes
- Prior art date
Links
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 title 1
- 229940100607 GPR119 agonist Drugs 0.000 title 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382114 | 2009-07-15 | ||
| US24544509P | 2009-09-24 | 2009-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000006A true DOP2012000006A (es) | 2012-01-31 |
Family
ID=43449712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000006A DOP2012000006A (es) | 2009-07-15 | 2012-01-11 | Agonista de gpr119 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8207344B2 (enExample) |
| EP (1) | EP2454251A1 (enExample) |
| JP (1) | JP5715127B2 (enExample) |
| KR (1) | KR101365854B1 (enExample) |
| CN (1) | CN102471313B (enExample) |
| AR (1) | AR077638A1 (enExample) |
| AU (1) | AU2010273642B2 (enExample) |
| BR (1) | BRPI1015921A2 (enExample) |
| CA (1) | CA2764906C (enExample) |
| CO (1) | CO6480977A2 (enExample) |
| CR (1) | CR20120012A (enExample) |
| DO (1) | DOP2012000006A (enExample) |
| EA (1) | EA020540B1 (enExample) |
| EC (1) | ECSP12011606A (enExample) |
| IL (1) | IL216776A0 (enExample) |
| MA (1) | MA33428B1 (enExample) |
| MX (1) | MX2012000704A (enExample) |
| NZ (1) | NZ597125A (enExample) |
| PE (1) | PE20121045A1 (enExample) |
| SG (1) | SG177646A1 (enExample) |
| TN (1) | TN2012000002A1 (enExample) |
| TW (1) | TWI429634B (enExample) |
| WO (1) | WO2011008663A1 (enExample) |
| ZA (1) | ZA201200227B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL377847A1 (pl) | 2003-01-14 | 2006-02-20 | Arena Pharmaceuticals Inc. | 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012135570A1 (en) * | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| JP6047144B2 (ja) | 2011-04-08 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 置換シクロプロピル化合物、このような化合物を含有する組成物および処置方法 |
| WO2012170702A1 (en) * | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
| EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
| EP2760855B1 (en) | 2011-09-30 | 2017-03-15 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes |
| WO2013062835A1 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| EP2771000B1 (en) | 2011-10-24 | 2016-05-04 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
| US9018224B2 (en) | 2011-11-15 | 2015-04-28 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
| WO2013187646A1 (en) * | 2012-06-12 | 2013-12-19 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for gpr119 agonist |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2014052619A1 (en) * | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
| CN110028494A (zh) * | 2013-11-26 | 2019-07-19 | 株式会社钟根堂 | 酰胺衍生物、其立体异构体或其药学上可接受的盐及包含其的药物组合物 |
| KR101651505B1 (ko) * | 2014-05-02 | 2016-08-29 | 현대약품 주식회사 | 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| KR102883123B1 (ko) | 2015-06-22 | 2025-11-10 | 아레나 파마슈티칼스, 인크. | Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염 |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL377847A1 (pl) * | 2003-01-14 | 2006-02-20 | Arena Pharmaceuticals Inc. | 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia |
| CA2661371A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CA2697551C (en) | 2007-09-20 | 2013-03-12 | Irm Llc | Piperidine derivatives as modulators of gpr119 activity |
-
2010
- 2010-07-06 AR ARP100102424A patent/AR077638A1/es not_active Application Discontinuation
- 2010-07-08 TW TW099122534A patent/TWI429634B/zh not_active IP Right Cessation
- 2010-07-12 AU AU2010273642A patent/AU2010273642B2/en not_active Ceased
- 2010-07-12 MX MX2012000704A patent/MX2012000704A/es active IP Right Grant
- 2010-07-12 CA CA2764906A patent/CA2764906C/en not_active Expired - Fee Related
- 2010-07-12 EP EP10734412A patent/EP2454251A1/en not_active Withdrawn
- 2010-07-12 CN CN201080031375.4A patent/CN102471313B/zh not_active Expired - Fee Related
- 2010-07-12 EA EA201270169A patent/EA020540B1/ru not_active IP Right Cessation
- 2010-07-12 PE PE2012000041A patent/PE20121045A1/es not_active Application Discontinuation
- 2010-07-12 WO PCT/US2010/041645 patent/WO2011008663A1/en not_active Ceased
- 2010-07-12 BR BRPI1015921A patent/BRPI1015921A2/pt not_active IP Right Cessation
- 2010-07-12 JP JP2012520691A patent/JP5715127B2/ja not_active Expired - Fee Related
- 2010-07-12 US US12/834,054 patent/US8207344B2/en not_active Expired - Fee Related
- 2010-07-12 KR KR1020127000996A patent/KR101365854B1/ko not_active Expired - Fee Related
- 2010-07-12 MA MA34531A patent/MA33428B1/fr unknown
- 2010-07-12 NZ NZ597125A patent/NZ597125A/xx not_active IP Right Cessation
- 2010-07-12 SG SG2012002523A patent/SG177646A1/en unknown
-
2011
- 2011-12-05 IL IL216776A patent/IL216776A0/en unknown
- 2011-12-29 CO CO11181048A patent/CO6480977A2/es active IP Right Grant
-
2012
- 2012-01-02 TN TNP2012000002A patent/TN2012000002A1/en unknown
- 2012-01-09 CR CR20120012A patent/CR20120012A/es unknown
- 2012-01-11 ZA ZA2012/00227A patent/ZA201200227B/en unknown
- 2012-01-11 DO DO2012000006A patent/DOP2012000006A/es unknown
- 2012-01-13 EC EC2012011606A patent/ECSP12011606A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201114757A (en) | 2011-05-01 |
| CN102471313B (zh) | 2014-06-04 |
| KR101365854B1 (ko) | 2014-02-21 |
| AU2010273642B2 (en) | 2014-03-13 |
| ECSP12011606A (es) | 2012-02-29 |
| EP2454251A1 (en) | 2012-05-23 |
| CO6480977A2 (es) | 2012-07-16 |
| WO2011008663A1 (en) | 2011-01-20 |
| ZA201200227B (en) | 2013-06-26 |
| US8207344B2 (en) | 2012-06-26 |
| JP5715127B2 (ja) | 2015-05-07 |
| CA2764906A1 (en) | 2011-01-20 |
| AR077638A1 (es) | 2011-09-14 |
| PE20121045A1 (es) | 2012-08-09 |
| TN2012000002A1 (en) | 2013-09-19 |
| JP2012533546A (ja) | 2012-12-27 |
| NZ597125A (en) | 2013-08-30 |
| BRPI1015921A2 (pt) | 2016-04-26 |
| CN102471313A (zh) | 2012-05-23 |
| MX2012000704A (es) | 2012-03-07 |
| AU2010273642A1 (en) | 2012-01-19 |
| KR20120024964A (ko) | 2012-03-14 |
| IL216776A0 (en) | 2012-03-01 |
| MA33428B1 (fr) | 2012-07-03 |
| CA2764906C (en) | 2014-06-10 |
| EA020540B1 (ru) | 2014-11-28 |
| CR20120012A (es) | 2012-03-28 |
| TWI429634B (zh) | 2014-03-11 |
| SG177646A1 (en) | 2012-02-28 |
| US20110015199A1 (en) | 2011-01-20 |
| EA201270169A1 (ru) | 2012-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2012000006A (es) | Agonista de gpr119 | |
| CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
| CL2012000937A1 (es) | Compuestos heterociclicos espiro derivados de ciclohexano, inhibidores de hsl; procedimiento de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de diabetes, sindrome metabolico, dislipidemia, aterosclerosis u obesidad. | |
| EA201170151A1 (ru) | Пиперидиниловые агонисты gpcr | |
| EA201100037A1 (ru) | Органические соединения | |
| MX2012012527A (es) | Compuestos quimicos. | |
| ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| EA200900877A1 (ru) | Пиперидиновые агонисты gpcr | |
| SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| CL2012003681A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes. | |
| MX2009007180A (es) | Agonistas del receptor acoplado a la proteina g de la piperidina. | |
| CL2008001049A1 (es) | Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad. | |
| CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
| ATE557023T1 (de) | Piperidinylverbindungen als gpcr-agonisten | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| CL2010000804A1 (es) | Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer. | |
| CL2008000110A1 (es) | Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos. | |
| BRPI0912890A2 (pt) | composição farmacêutica para o tratamento de ejaculação precoce | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. |